L'usine de bioconjugués de Piramal Pharma Solutions à Grangemouth, au Royaume-Uni, reçoit des certificats de BPF de la MHRA mis à jour

Core Points - Piramal Pharma Solutions has announced that its Grangemouth facility in the UK has received updated MHRA Good Manufacturing Practice (GMP) certificates following a successful compliance report and office inspection [1][7]. - The updated certificates cover all activities within the Helix building, including the manufacturing and testing of drug substances for clinical and commercial purposes, as well as warehouses and laboratories [2][7]. - The Grangemouth site is dedicated to the development and manufacturing of antibody-drug conjugates (ADCs) and plays a crucial role in the ADCelerate™ program, which aims to expedite the availability of life-saving bioconjugate treatments to patients [3][4]. Company Commitment - The updated MHRA GMP certificates reflect Grangemouth's ongoing commitment to excellence, evidenced by its strong regulatory history and a series of successful inspections by various health authorities, including the USFDA and PMDA [4][5]. - Peter DeYoung, CEO of Piramal Global Pharma, emphasized that the success of the Grangemouth facility in meeting high-quality standards enables the site to support partners in the critical area of drug development [5]. Company Overview - Piramal Pharma Solutions is a leading global Contract Development and Manufacturing Organization (CDMO) that offers end-to-end development and manufacturing solutions throughout the drug lifecycle [6]. - The company operates a global network of integrated facilities across North America, Europe, and Asia, providing a comprehensive range of services, including drug discovery, process development, and clinical trial supplies [6]. - Piramal Pharma Limited, the parent company, consists of various segments, including Piramal Critical Care and Piramal Consumer Healthcare, and has strategic investments in biotherapeutics and vaccine segments through partnerships [8].